Today: 13 March 2026
Subscribe
Browse Category

NYSE:GSK 11 November 2025 - 17 December 2025

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.
17 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK faces a key FDA decision on depemokimab for severe asthma and nasal polyps on Dec. 16, following recent EU regulatory backing for the drug and other respiratory products. GSK ADRs last traded at $48.81, while London shares opened at 1,816.50p. Analysts are watching for potential shifts in revenue forecasts and valuation as regulatory outcomes approach.
15 December 2025
··
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.
10 December 2025
···
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.
9 December 2025
···
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK shares closed at $47.9 on November 28, just below a 52-week high, after a year-to-date gain of about 30–40%. The company beat earnings expectations in Q2 and Q3, raised full-year guidance, and saw its cancer drug Blenrep re-approved in major markets. CEO Emma Walmsley will step down December 31, with Luke Miels to take over January 1. Most analysts rate the stock a “Hold” despite recent outperformance.
1 December 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

GSK shares closed up 0.23% at 1,776p in London on Thursday, trading between 1,772p and 1,790p on light volume. Jefferies raised its target price to 2,100p and reiterated a “Buy” rating. Recent R&D announcements and a new oncology collaboration with LTZ Therapeutics continued to influence sentiment. Over the past year, GSK shares have gained about 36%.
20 November 2025
··
1 2

Stock Market Today

  • Indian Stock Market Faces Pressure on March 13 Amid Rising Crude Oil Prices
    March 12, 2026, 11:33 PM EDT. The Indian stock market benchmarks, Sensex and Nifty 50, are set for a weak opening on March 13 as rising crude oil prices linked to the US-Iran conflict weigh on investor sentiment. The Sensex fell 829.29 points to 76,034.42 and Nifty 50 closed below 23,700, signaling continued correction. Technical analysis indicates possible trading ranges with support for Nifty 50 around 23,500-23,400 and resistance near 23,850. Derivatives data shows put and call writing suggesting limited range movement ahead. Analysts advise caution with volatile and non-directional market conditions persisting. A clear breakout above resistance levels is needed to confirm a trend reversal
Go toTop